Soligenix expands European Medical Advisory Board for CTCL

Soligenix (SNGX) announced the expansion of its European Medical Advisory Board to provide additional medical/clinical strategic guidance to the company as it advances its confirmatory Phase 3 multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of HyBryte in the treatment of cutaneous T-cell lymphoma patients with early-stage disease. This confirmatory, 18-week study is expected to enroll approximately 80 patients and is targeted to report top-line results in the second half of 2026.